The speaker contrasts a U.S. tendency to address harms through subsequent litigation with Europe’s tendency to regulate preemptively to avoid harm, saying both seek good outcomes but one approach is more conducive to innovation.

“patients there's sort of regulation versus litigation trade-offs you know in the U.S. you first can often not every time like you know FDA and so on does regulate some areas but in many cases the sort of bad things happen someone sues someone else and then there's a law based on that in Europe they try to often avoid any harm to anyone and regulate before and both are you know trying to do the best thing but you know some is actually more amenable to innovation”